Fresenius Kabi and Formycon AG have announced that Otulfi (ustekinumab-aauz), an ustekinumab biosimilar for the reference product Stelara (ustekinumab), developed by Formycon AG, is now available in the United States. About Otulfi Otulfi is indicated for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis in adult patients, moderate to severely plaque psoriasis for adult patients and pediatric patients six years or older, who are candidates for phototherap...